Operator
Good morning, and welcome to the Iveric Bio first-quarter 2021 earnings conference call. [Operator instructions] Please note this call is being recorded. I would now like to turn the conference over to Kathy Galante, senior vice president, investor relations. Please go ahead.
Kathy Galante
Senior Vice President, Investor Relations
Good morning, and welcome to Iveric Bio s conference call. Representing Iveric Bio today are Glenn Sblendorio, chief executive officer; Pravin Dugel, president; David Carroll, chief financial officer; Dhaval Desai, chief development officer; Abraham Scaria, chief scientific officer; and Keith Westby, chief operating officer. I would like to remind you that today, we will be making statements relating to Iveric Bio s future expectations regarding operational, financial and research and development matters, including statements regarding our expectations for patient enrollment and patient retention in GATHER2, our second Phase 3 clinical trial
Type 1 Diabetes and Transgender Identity: Is There a Link? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
RELATED:
Does Treatment With Systemic Estrogen Reduce Nocturia, or Waking to Urinate?
Nocturia is caused by the loss of estrogen, which causes bladder dysfunction, night sweats, sleep disorders, and alters kidney function. The efficacy of hormone therapy (HT or HRT) on menopause-related nocturia has not been studied much. While topical vaginal estrogen has been shown in past studies to help reduce symptoms linked with the genitourinary syndrome of menopause (GSM), the authors of the new study wanted to look at the effect of systemic estrogen as well, including the effects of other hormone combinations and the new therapy called tissue-selective estrogen complex (TSEC) on nocturia.
Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel.
Glycostem and Ghent University sign license agreement on NK cell therapy technology
- Significant positive effect on production time of Glycostem s lead product oNKord
, and future CAR-NK and TCR-NK therapies
OSS, Netherlands, Dec. 17, 2020 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant positive impact on the production time of Glycostem s lead product oNKord